A U.S. appeals court said Novartis AG could begin selling the first knockoff of a biotech drug on Sept. 2, a key step in efforts to contain spending on high-cost therapies through lower-priced competition.
from WSJ.com: US Business http://ift.tt/1VqYRhv
via IFTTT
No comments:
Post a Comment